The association between virologic response and human immunodeficiency virus type 1 (HIV-1) subtype was investigated in 113 HIV-1-infected children randomly assigned to receive zidovudine plus lamivudine, zidovudine plus abacavir, or lamivudine plus abacavir in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. Symptomatic children (n = 68) also received nelfinavir; asymptomatic children (n = 45) were randomly assigned to receive nelfinavir or placebo. HIV-1 subtypes A, B, C, D, F, G, H, A/E, and A/G were found in 15%, 41%, 16%, 9%, 5%, 2%, 1%, 5%, and 7% of the children, respectively. Resistance assay failure rates were higher for non-B subtypes than for B subtypes (genotype, P = .01; phenotype, P = .02). HIV-1 subtype was not associated with virologic response at 24 and 48 weeks after initiation of treatment. No differences were observed in the frequency of development of resistance mutations L90M (P = 1.00) and D30N (P = .61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found.

Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial / D. Pillay, A.S. Walker, D.M. Gibb, A. De Rossi, S. Kaye, M. Ait-Khaled, M. Munoz-Fernandez, A. Babiker, C. Boucher, C. Loveday, M.M. Fernandez, C. Rouzioux, J.-. Aboulker, A. Compagnucci, J. Darbyshire, M. Debre, M. Gersten, C. Giaquinto, A. Jones, D. Dunn, L. Harper, D. Johnson, P. Kelleher, L. Mc Gee, A. Newberry, A. Poland, V. Eliette, S. Leonardo, Y. Saidi, S. Blanche, A.B. Bohlin, K. Butler, G. Castelli-Gattinara, P. Clayden, A. Faye, C. Griscelli, I. Grosch-Worner, J. Levy, H. Lyall, M.M. Pena, D. Nadal, C. Peckham, J.T.R. Amador, L. Rosado, C. Rudin, H. Scherpbier, M. Sharland, P.A. Tovo, G. Tudor-Williams, A. Volny-Anne, U. Wintergerst, M. Hainaut, A. Peltier, G. Zissis, M.D. Negra, W. Queiroz, L.P. Feitosa, D. Oliveira, F. Mechinaud, S. Billaudel, V. Ferre, R. Weigel, K. Seel, C. Feiterna-Sperling, C. Muller, V. Wahn, T. Niehues, J. Ndagijimana, G. Horneff, N. Vente, R. Ganschow, T. Simon, H. Pfister, G. Notheis, G. Strotmann, S. Schlieben, E. Hayes, M. O'Mara, J.M. Byrne, L. Battisti, M. Duse, S. Timpano, E. Uberti, P. Crispino, P. Carrara, F. Fomia, A. Manca, L. Galli, M. De Martino, F. Fioredda, E. Pontali, M. Cellini, C. Baraldi, M. Portolani, M. Meacci, P. Pietrosemoli, A. Guarino, M.I. Spagnuola, R.B. Canani, P. Laccetti, M. Gobbo, V. Giacomet, R. D'Elia, M. Zanchetta, D. Caselli, A. Maccabruni, E. Cattaneo, V. Landini, S. Bernardi, A. Krzysztofiak, C. Tancredi, P. Rossi, L. Pansani, E. Palomba, C. Gabiano, A. Mazza, G. Rossetti, R. Nicolin, A. Timillero, F. Candeias, G. Santos, M.L.R. Ribeiro, M.C. Almeida, M.H. Lourenco, R. Antunes, M.J.M. Pena, P.M. Santos, L.C. Calavia, O. Delgado, N. Matamoros, A. Foot, H. Kershaw, O. Caul, W. Tarnow-Mordi, J. Petrie, P. Mc Intyre, K. Appleyard, K. Sloper, V. Shah, A. Aali, J. Mok, R. Russell, S. Burns, V. Novelli, N. Klein, S. Ewen, C. Ball, K. Himid, D. Nayagam, D. Graham, M. Zuckerman, P. Bracken, E. Cooper, T. Fisher, R. Barrie, V.V. Someren, K. Moshal, T. Gundlach, J. Norman, M. Richardson, S. Donaghy, J. Booth, A. Shipp, D. Butcher, J. White, S. Head, C. Stainsby, G.D. Mont, S. O'Shea, A. Tilsey, A. Finn, S. Choo, R. Lakshman, G. Bell, A. Siddens. - In: ANTIVIRAL THERAPY. - ISSN 2040-2058. - 186:5(2002), pp. 617-625. [10.1086/342680]

Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial

A. Faye;L. Battisti;V. Giacomet;R. D'Elia;C. Tancredi;R. Antunes;
2002

Abstract

The association between virologic response and human immunodeficiency virus type 1 (HIV-1) subtype was investigated in 113 HIV-1-infected children randomly assigned to receive zidovudine plus lamivudine, zidovudine plus abacavir, or lamivudine plus abacavir in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. Symptomatic children (n = 68) also received nelfinavir; asymptomatic children (n = 45) were randomly assigned to receive nelfinavir or placebo. HIV-1 subtypes A, B, C, D, F, G, H, A/E, and A/G were found in 15%, 41%, 16%, 9%, 5%, 2%, 1%, 5%, and 7% of the children, respectively. Resistance assay failure rates were higher for non-B subtypes than for B subtypes (genotype, P = .01; phenotype, P = .02). HIV-1 subtype was not associated with virologic response at 24 and 48 weeks after initiation of treatment. No differences were observed in the frequency of development of resistance mutations L90M (P = 1.00) and D30N (P = .61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found.
Antiviral Agents; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; RNA, Viral; Reverse Transcriptase Inhibitors
Settore MED/38 - Pediatria Generale e Specialistica
Article (author)
File in questo prodotto:
File Dimensione Formato  
186-5-617.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 151.67 kB
Formato Adobe PDF
151.67 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/728842
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 84
  • ???jsp.display-item.citation.isi??? ND
social impact